Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind multicenter study of SHR-1139 injection in moderate-to-severe plaque psoriasis
CTR20262800Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SHR-1139 in plaque psoriasis (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Proportion of participants achieving PASI 100. Started Aug 2026; status: active.
02
Drugs
SHR-1139
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20262800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262800.